Avaliação do papel de metalo e organo compostos no câncer: Atividades antiangiogênica e antitumoral

Abstract

Breast cancer (BC) is the most common tumor type in women and a major public health problem. Due to its molecular heterogeneity, it is classified into subtypes according to the expression of hormone receptors and Human Epidermal Growth Factor Receptor 2 (HER2). In this work, we highlight the therapeutic action of a nanoformulation (LUV/CBP-01N-PARPi) on tumor angiogenesis of Triple-Negative BC (TNBC) and of an organic compound [4-(1H-tetrazol-1-yl)phenyl][4-((4-chlorophenyl)sulfonyl)piperazin-1-yl]methanone - Compound 3) on Luminal A BC. TNBC is characterized by the absence of hormone receptors and HER2 and by being a subtype with greater aggressiveness and metastatic rate. Luminal A BC, the most common subtype of BC, is characterized by the expression of hormone receptors, and despite its responsiveness to hormone therapy, the number of cases with resistance to this therapy has been increasing. Here, we demonstrate that LUV/CBP-01N-PARPi inhibits angiogenesis in vitro, both by acting directly on endothelial cells and by modulating the secretome of TNBC. Compound 3, described here, stands out as a promising antitumor agent, with its action proven in vitro. In addition, the modulation of purinergic signaling by treatments was investigated here. Tests in animal models and other experimental approaches are needed to better elucidate the therapeutic potential of these compounds.